SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to a strategic $14.2 billion deal to regain full ownership of its Ireland-based Fab 34, a move perceived as a major vote of confidence in the company's manufacturing and AI-driven growth trajectory. The community is actively debating the stock's future, with many interpreting the heavy capital reinvestment as a clear indicator that major new customer contracts are imminent.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors react to a nationwide subscription price hike, which analysts view as a strategic move to boost revenue and fund a massive content budget. The community is actively debating the impact on subscriber churn versus the company's pricing power, while the stock shows relative strength and bullish momentum as traders monitor key technical breakout levels.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is trending following the recent FDA approval of its rare disease drug, VYKAT XR, which has triggered intense market activity and discussions regarding the company's valuation, potential for a future buyout, and its ability to execute a successful commercial launch. Investors and traders are closely monitoring price action as the company transitions into a commercial-stage entity, with active debate surrounding its long-term growth prospects versus risks of dilution or volatility.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is currently trending as shareholders analyze the strategic implications of parent company Centurium Capitals acquisition of Blue Bottle Coffee. While the community remains divided over potential conflicts of interest versus synergistic growth, investors are closely monitoring for signs of a long-anticipated U.S. exchange relisting and are actively debating the stock's future valuation amid shifting institutional ownership.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to heightened speculation surrounding a potential buyout, as market participants monitor recent biotech deal flow and comments from industry observers. While some investors focus on the company's robust obesity drug pipeline and late-stage clinical progress, others are actively debating the impact of competitive GLP-1 developments and broader macroeconomic volatility on its near-term valuation.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending as the market reacts to the definitive agreement to acquire Soleno Therapeutics for $2.9 billion. Community sentiment is mixed, with active debate regarding whether the acquisition effectively addresses Neurocrine's need for pipeline growth or if the premium paid for the rare-disease asset signals a strategic overpay.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

The community is actively discussing $BUTTCOIN as a long-standing meme, with supporters promoting it as a humorous, culturally significant alternative to traditional cryptocurrencies. Many discussions center on the project's historical roots and its potential to capture significant mindshare, while others remain skeptical about the influx of speculative meme assets in the market.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria Group is experiencing significant momentum driven by a strong commitment to shareholder returns, including a recent dividend increase and expanded share repurchase program, which have reinforced investor confidence despite ongoing volume declines in traditional tobacco products. The community is actively discussing the stock's resilience as a defensive income play, with many highlighting the successful rollout of the 'on!' nicotine pouch line and the company's aggressive pricing strategy as key drivers offsetting structural headwinds.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing heightened activity as the community discusses its potential for a short squeeze driven by extremely limited share availability and high borrowing fees. Traders are actively comparing its current price action and low-float structure to historical runs, with significant debate occurring between those betting on a parabolic breakout and skeptics warning of pump-and-dump risks.

Legence Corp. engages in engineering, consultation, installation, and maintenance services for mission-critical systems in buildings. It operates through the Engineering & Consulting and Installation & Maintenance segments. The Engineering & Consulting segment designs HVAC and other MEP systems for buildings, develops strategies to reduce energy usage and make buildings more sustainable, and provides program and project management services for customers’ installation and retrofit projects. The Installation & Maintenance segment fabricates and installs HVAC systems, process piping, and other MEP systems in new and existing industrial, commercial, and institutional buildings and provides ongoing preventative and corrective maintenance services for those systems. The company was founded on January 9, 2025 and is headquartered in San Jose, CA.

Legence Corp. - Ordinary Shares - Class A

Legence Corp

Legence Corp ($LGN) is seeing significant investor attention following strong earnings results and positive updates from multiple analysts who have raised their price targets. While some community members remain skeptical of recent IPO performance and potential insider selling, bulls are highlighting the stock as a long-term play on data center infrastructure and high-efficiency building systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen, which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. The company also develops and invests in stem cell and medical technology. Diamyd Medical was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.

Diamyd Medical AB - Ordinary Shares - Class B

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

DYMDF
Diamyd Medical AB - Ordinary Shares - Class B

Feed

News

Sentiment

Fundamentals

Info

Latest DYMDF News

DYMDFDiamyd Medical AB - Ordinary Shares - Class B